Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
BMS Active Not Yet Recruiting Study icon

Active, Not Recruiting

Trial ID CC-92480-MM-002  |   NCT03989414

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

Warning icon
Sorry, this study is no longer accepting new participants, but is still ongoing.
You may click the “Check if you qualify” button and answer a few questions about your health to find out if you might be a match to another study.

Summary

  • Phase 1/Phase 2
  • Male and Female Gender icon
  • 18+
    Age Range
  • BMS Active Not Yet Recruiting Study icon
    Active, Not Recruiting

Overview

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

Key Eligibility Criteria

Inclusion Criteria: • Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2 For participants in Cohorts A, B, C, D, E, F, H, I, J, and K the following inclusions will also apply: - Documented diagnosis of multiple myeloma (MM) and measurable disease - Documented disease progression during or after their last antimyeloma regimen - Achieved a response (minimal response [MR] or better) to at least 1 prior treatment regimen Exclusion Criteria: - Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) or clinically significant amyloidosis - Known central nervous system (CNS) involvement with myeloma - Received immunosuppressive medication within the last 14 days of initiating study treatment - Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment Other protocol-defined inclusion/exclusion criteria apply

Treatment Options

Study Arms

ASSIGNED INTERVENTION

Study Arms

Experimental: Cohort A: CC-92480 with bortezomib and dexamethasone

ASSIGNED INTERVENTION
  • Drug: CC-92480, Bortezomib, Dexamethasone

Study Arms

Experimental: Cohort C: CC-92480 with carfilzomib and dexamethasone

ASSIGNED INTERVENTION
  • Drug: CC-92480, Dexamethasone, Carfilzomib

Study Arms

Experimental: Cohort D: CC-92480 with bortezomib and dexamethasone

ASSIGNED INTERVENTION
  • Drug: CC-92480, Dexamethasone, Bortezomib

Study Arms

Experimental: Cohort F: CC-92480 with carfilzomib and dexamethasone

ASSIGNED INTERVENTION
  • Drug: CC-92480, Dexamethasone, Carfilzomib

Study Arms

Experimental: Cohort G: CC-92480 with bortezomib and dexamethasone

ASSIGNED INTERVENTION
  • Drug: CC-92480, Bortezomib, Dexamethasone

Study Arms

Experimental: Cohort H: CC-92480 with elotuzumab and dexamethasone

ASSIGNED INTERVENTION
  • Drug: Elotuzumab, CC-92480, Dexamethasone

Study Arms

Experimental: Cohort I: CC-92480 with isatuximab and dexamethasone

ASSIGNED INTERVENTION
  • Drug: CC-92480, Dexamethasone, Isatuximab

Study Arms

Experimental: Cohort J: CC-92480 with elotuzumab and dexamethasone

ASSIGNED INTERVENTION
  • Drug: CC-92480, Elotuzumab, Dexamethasone

Study Arms

Experimental: Cohort K: CC-92480 with isatuximab and dexamethasone

ASSIGNED INTERVENTION
  • Drug: CC-92480, Isatuximab, Dexamethasone

Study Arms

Experimental: Subcohort B1: CC-92480 with daratumumab and dexamethasone

ASSIGNED INTERVENTION
  • Drug: Dexamethasone, CC-92480, Daratumumab

Study Arms

Experimental: Subcohort B2: CC-92480 with daratumumab and dexamethasone

ASSIGNED INTERVENTION
  • Drug: Dexamethasone, CC-92480, Daratumumab

Study Arms

Experimental: Subcohort B3: CC-92480 with daratumumab and dexamethasone

ASSIGNED INTERVENTION
  • Drug: Daratumumab, Dexamethasone, CC-92480

Study Arms

Experimental: Subcohort E1: CC-92480 with daratumumab and dexamethasone

ASSIGNED INTERVENTION
  • Drug: Daratumumab, Dexamethasone, CC-92480

Study Arms

Experimental: Subcohort E2: CC-92480 with daratumumab and dexamethasone

ASSIGNED INTERVENTION
  • Drug: Dexamethasone, Daratumumab, CC-92480

Study Arms

Experimental: Subcohort E3: CC-92480 with daratumumab and dexamethasone

ASSIGNED INTERVENTION
  • Drug: CC-92480, Dexamethasone, Daratumumab

Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you